Alpine Immune Sciences Inc (NASDAQ: ALPN) closed the day trading at $64.50 up 0.12% from the previous closing price of $64.42. On the day, 2972518 shares were traded.
Ratios:
For a better understanding of ALPN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.86 and its Current Ratio is at 7.86. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on April 09, 2024, initiated with a Buy rating and assigned the stock a target price of $55.
On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $44.
On October 18, 2023, Berenberg started tracking the stock assigning a Buy rating and target price of $18.Berenberg initiated its Buy rating on October 18, 2023, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 26 ’24 when Rickey James Paul sold 117,764 shares for $23.32 per share. The transaction valued at 2,745,830 led to the insider holds 0 shares of the business.
Rickey James Paul sold 236 shares of ALPN for $5,192 on Jan 25 ’24. The insider now owns 0 shares after completing the transaction at $22.00 per share. On Dec 28 ’23, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 1,364,849 shares for $18.35 each. As a result, the insider received 25,049,034 and left with 264,315 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 71.81 while its Price-to-Book (P/B) ratio in mrq is 11.87.
Stock Price History:
Over the past 52 weeks, ALPN has reached a high of $64.57, while it has fallen to a 52-week low of $6.71.
Shares Statistics:
A total of 60.35M shares are outstanding, with a floating share count of 47.05M. Insiders hold about 28.22% of the company’s shares, while institutions hold 68.40% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of -$0.41 for the current quarter, with a high estimate of -$0.29 and a low estimate of -$0.51, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.3 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.23 and -$1.95 for the fiscal current year, implying an average EPS of -$1.66. EPS for the following year is -$1.89, with 8 analysts recommending between -$1.23 and -$2.45.
Revenue Estimates
6 analysts predict $3.52M in revenue for the current quarter. It ranges from a high estimate of $10M to a low estimate of –$. As of the current estimate, Alpine Immune Sciences Inc’s year-ago sales were $9.39M, an estimated decrease of -62.50% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for ALPN’s current fiscal year. The highest revenue estimate was $40M, while the lowest revenue estimate was –$, resulting in an average revenue estimate of $15.67M. In the same quarter a year ago, actual revenue was $58.88M, down -73.40% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $16.29M in the next fiscal year. The high estimate is $40M and the low estimate is –$. The average revenue growth estimate for next year is up 4.00% from the average revenue estimate for this year.
